Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.
Trial Parameters
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * Body mass index (BMI) ≥27 kg/m² * Documented atrial fibrillation (paroxysmal or persistent) * Ability to participate in exercise training and follow study procedures * Access to a smartphone or device enabling rhythm monitoring * Provides written informed consent Exclusion Criteria: * Permanent atrial fibrillation * Unstable angina pectoris or acute coronary syndrome within the past 3 months * Participation in other lifestyle or drug weight reduction trials * Significant left ventricular dysfunction (ejection fraction \<30%) * Severe valvular heart disease or planned cardiac surgery * Severe heart failure (NYHA class IV) or severe angina (CCS class IV) * Unstable coronary artery disease or recent myocardial infarction * Severe pulmonary disease limiting exercise capacity * Active malignancy * Autoimmune or systemic inflammatory diseases * Severe renal or hepatic failure * Memory disease or significant cognitive impairment * Unstable psychiatric c